Switch theme
Sign up to access all valuation multiples
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease.
2012
288
LTM Revenue $89.5M
LTM EBITDA -$144M
$707M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
WAVE Life Sciences has a last 12-month revenue (LTM) of $89.5M and a last 12-month EBITDA of -$144M.
In the most recent fiscal year, WAVE Life Sciences achieved revenue of $108M and an EBITDA of -$102M.
WAVE Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See WAVE Life Sciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $89.5M | XXX | $108M | XXX | XXX | XXX |
| Gross Profit | $88.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 99% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$144M | XXX | -$102M | XXX | XXX | XXX |
| EBITDA Margin | -161% | XXX | -94% | XXX | XXX | XXX |
| EBIT | -$138M | XXX | -$110M | XXX | XXX | XXX |
| EBIT Margin | -155% | XXX | -102% | XXX | XXX | XXX |
| Net Profit | -$127M | XXX | -$97.0M | XXX | XXX | XXX |
| Net Margin | -141% | XXX | -90% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, WAVE Life Sciences's stock price is $6.
WAVE Life Sciences has current market cap of $926M, and EV of $707M.
See WAVE Life Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $707M | $926M | XXX | XXX | XXX | XXX | $-0.82 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, WAVE Life Sciences has market cap of $926M and EV of $707M.
WAVE Life Sciences's trades at 6.5x EV/Revenue multiple, and -6.9x EV/EBITDA.
Equity research analysts estimate WAVE Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
WAVE Life Sciences has a P/E ratio of -7.3x.
See valuation multiples for WAVE Life Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $926M | XXX | $926M | XXX | XXX | XXX |
| EV (current) | $707M | XXX | $707M | XXX | XXX | XXX |
| EV/Revenue | 7.9x | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBITDA | -4.9x | XXX | -6.9x | XXX | XXX | XXX |
| EV/EBIT | -5.1x | XXX | -6.4x | XXX | XXX | XXX |
| EV/Gross Profit | 8.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.3x | XXX | -9.5x | XXX | XXX | XXX |
| EV/FCF | -4.2x | XXX | -4.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWAVE Life Sciences's last 12 month revenue growth is -29%
WAVE Life Sciences's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.8M for the same period.
WAVE Life Sciences's rule of 40 is -81% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
WAVE Life Sciences's rule of X is -234% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for WAVE Life Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -29% | XXX | -23% | XXX | XXX | XXX |
| EBITDA Margin | -161% | XXX | -94% | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -81% | XXX | -123% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -234% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 147% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 202% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
WAVE Life Sciences acquired XXX companies to date.
Last acquisition by WAVE Life Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . WAVE Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was WAVE Life Sciences founded? | WAVE Life Sciences was founded in 2012. |
| Where is WAVE Life Sciences headquartered? | WAVE Life Sciences is headquartered in United States of America. |
| How many employees does WAVE Life Sciences have? | As of today, WAVE Life Sciences has 288 employees. |
| Who is the CEO of WAVE Life Sciences? | WAVE Life Sciences's CEO is Dr. Paul B. Bolno, M.B.A.,M.D.. |
| Is WAVE Life Sciences publicy listed? | Yes, WAVE Life Sciences is a public company listed on NAS. |
| What is the stock symbol of WAVE Life Sciences? | WAVE Life Sciences trades under WVE ticker. |
| When did WAVE Life Sciences go public? | WAVE Life Sciences went public in 2015. |
| Who are competitors of WAVE Life Sciences? | Similar companies to WAVE Life Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of WAVE Life Sciences? | WAVE Life Sciences's current market cap is $926M |
| What is the current revenue of WAVE Life Sciences? | WAVE Life Sciences's last 12 months revenue is $89.5M. |
| What is the current revenue growth of WAVE Life Sciences? | WAVE Life Sciences revenue growth (NTM/LTM) is -29%. |
| What is the current EV/Revenue multiple of WAVE Life Sciences? | Current revenue multiple of WAVE Life Sciences is 7.9x. |
| Is WAVE Life Sciences profitable? | Yes, WAVE Life Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of WAVE Life Sciences? | WAVE Life Sciences's last 12 months EBITDA is -$144M. |
| What is WAVE Life Sciences's EBITDA margin? | WAVE Life Sciences's last 12 months EBITDA margin is -161%. |
| What is the current EV/EBITDA multiple of WAVE Life Sciences? | Current EBITDA multiple of WAVE Life Sciences is -4.9x. |
| What is the current FCF of WAVE Life Sciences? | WAVE Life Sciences's last 12 months FCF is -$167M. |
| What is WAVE Life Sciences's FCF margin? | WAVE Life Sciences's last 12 months FCF margin is -186%. |
| What is the current EV/FCF multiple of WAVE Life Sciences? | Current FCF multiple of WAVE Life Sciences is -4.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
